Olga L. Kochneva

Olga L. Kochneva

Auto-generated profile, based on publicly available information

Olga L. Kochneva

City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2022 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
ОKОlga L. Kochneva
Оlga L. Kochneva
Maria KislovaMaria Kislova
Maria Kislova
EZEvgenya I. Zhelnova
Evgenya I. Zhelnova
APAndrei A. Petrenko
Andrei A. Petrenko
EBElena A. Baryakh
Elena A. Baryakh
ENEugene Nikitin
Eugene Nikitin
We describe a retrospective cohort, 156 patients with chronic lymphocytic leukemia (CLL) diagnosed with COVID-19, analyze factors associated with a severe disease course and the effects of various treatment regimens. Anti-SARS-CoV-2 IgG and IgM levels are significantly lower. Patients with CLL are more likely to have a severe course of COVID-19, with IL-6 levels acting as a consistent biomarker of disease severity. Ten patients had recurrent episodes, fatality rate of 20%. Overall survival did not differ between patients receiving ibrutinib monotherapy and anti-CD20 antibodies ± chemotherapy. It seems that the immunodeficiency inherent to CLL influences outcomes to a larger degree than does the treatment. Glucocorticoids are not associated with significant OS improvement whereas anti-cytokine compounds usage seemed to be beneficial in patients with mild pulmonary involvement. Our data attest to the necessity of reorganizing health care for patients with CLL. Early administration of effective antiviral compounds and tailored vaccination protocols are warranted.

10 December 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
MMMarat Mingalimov
Marat Mingalimov
EBE. A. Baryakh
E. A. Baryakh
AMA. V. Misyurin
A. V. Misyurin
LKL. A. Kesaeva
L. A. Kesaeva
AMA. S. Mkrtchyan
A. S. Mkrtchyan
MLM. A. Lysenko
M. A. Lysenko
Background. Diffuse large B-cell lymphoma (DLBCL) is a potentially curable biologically heterogeneous lymphatic tumor. Standard R-CHOP therapy shows disappointing results, both immediate and longterm. To improve efficacy without additional toxicity, it is worth considering the possibility of using biologically oriented therapy.Aim. To evaluate the clinical efficacy and toxicity of the genotypedirected R-CHOP-X in patients with newly diagnosed DLBCL in real clinical practice.Materials and methods. A single-center prospective interventional clinical study included 30 patients with newly diagnosed DLBCL between September 2023 and September 2024. The median age was 60 (38–78) years. According to the international prognostic index, 23 (77 %) patients were classified as having a high risk of progression. Genotype incidence in the study cohort: MCD – 7 %, N1 – 20 %, BN2 – 7 %, EZB– 16 %, ST2 – 7 %, NOS – 43 %.Results. 30 patients received personalized genotype-directed therapy. Of these, 21 (70 %) patients completed treatment: the overall response rate was 100 % (complete metabolic response – 100 %). 9 (30 %) patients continue therapy: the overall response rate is 100 %. At 12 months, overall survival and progression-free survival were 100 % (95 % confidence interval 100 %). Hematological toxicity was assessed depending on the number of cycles (n = 144): grade III–I neutropenia was detected in 7 % of cycles, grade III–I anemia and grade III–I thrombocytopenia in 1.4 and 3.5 % of cycles, respectively. Non-hematological toxicity was generally grade ≤I–II.Conclusion. The results of this clinical trial are promising and provide preliminary evidence for the benefit of personalized genotype-directed antitumor therapy in newly diagnosed DLBCL. This therapeutic strategy demonstrates high clinical efficacy, particularly in the main target group – DLBCL with a high risk of progression with low toxicity. Further randomized studies are needed to confirm the effectiveness and implement the new approach in routine clinical practice.

10 December 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
EMElena N. Misyurina
Elena N. Misyurina
EZE. N. Zotina
E. N. Zotina
SGS. M. Gadzhieva
S. M. Gadzhieva
NCNatalia Chernova
Natalia Chernova
EKE. A. Karimova
E. A. Karimova
TST. A. Semina
T. A. Semina
Background. Multiple myeloma (MM) is the second most common oncohematological disease among malignant tumors of the hematopoietic and lymphoid tissues. According to epidemiological data, MM accounts for approximately 10–12 % of all hematological malignancies. An analysis of the main clinical parameters and treatment outcomes was conducted in patients with MM included in the registry of the Moscow Clinical Research Center “Hospital 52” in 2022–2025. Aim. To evaluate the clinical and hematological profile of MM patients, as well as to analyze the effectiveness of first-line antitumor therapy, including standard treatment regimens and high-dose chemotherapy programs followed by autologous hematopoietic stem cell transplantation. Materials and methods. The observational retrospective study included 325 patients with newly diagnosed MM: 147 (45.2 %) men, 178 (54.8 %) women. The median age at diagnosis was 67 (22–92) years. The number of patients aged 65 years and older was 194 (59.7 %). Antitumor therapy was carried out according to current clinical guidelines. In the first line of therapy, bortezomib was most often used, in the second – lenalidomide and monoclonal antibodies, in the third – monoclonal antibodies. Results. According to the International Staging System, 62.2 % of patients had stage III disease. Myeloma nephropathy was detected in 28.9 % of patients, with 20.3 % requiring programmed dialysis. Autologous hematopoietic stem cell transplantation was performed in 30.8 % of patients. Response to induction therapy: complete remission – 8.0 %; very good partial remission – 27.7 %; partial remission – 24.6 %. The best response rates were achieved with the use of monoclonal antibodies (66.6 % – complete remission + very good partial remission). With a median follow-up of 12.6 months, 1-year overall survival was 83.9 % (95 % confidence interval 82.3–85.4), 1-year progression-free survival was 75.8 % (95 % confidence interval 73.9–77.6). Conclusion. Using registry data allows us to characterize the MM patient population, evaluate the effectiveness of patient treatment, plan the work of the hematology center, forecast the funds required for the purchase of medications, and improve the organizational aspects of the hematology service in a multidisciplinary institution.

1 September 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
TTT. N. Tolstykh
T. N. Tolstykh
EME. N. Misyurina
E. N. Misyurina
MMMarat Mingalimov
Marat Mingalimov
EBE. A. Baryakh
E. A. Baryakh
EZE. I. Zhelnova
E. I. Zhelnova
MLM. A. Lysenko
M. A. Lysenko
Aim. To evaluate the acute myeloid leukemia (AML) treatment efficacy in adults in Moscow real clinical practice according to the Moscow Cancer Registry data.Materials and methods. We retrospectively collected data from the Moscow Cancer Registry on Moscow permanent residents who were primary diagnosed with AML from January 2019 to November 2023. The effectiveness of antitumor therapy was assessed by the complete remissions rate, relapses, deaths, and 3-year overall and relapse-free survival. Data analysis performed as of 01.12.2023.Results. According to the Moscow Cancer Registry, from 01.01.2019 to 01.12.2023, the diagnosis of AML (except for acute promyelocytic leukemia) was established in 752 patients with a median age at the time of diagnosis of 64 (19– 94) years. In the studied sample, females slightly predominated: women – 56.6 % (n = 426), men – 43.4 % (n = 326). Of all patients included in the study, 36 % (n = 275) received intensive chemotherapy, while 57 % (n = 427) received low-intensity chemotherapy, and the remaining 7 % (n = 50) patients received best supportive care. Early mortality (first 60 days) in the total group was 16 % (n = 123), 20 % (n = 149) of patients were refractory to the therapy. Complete remission was achieved by 63 % (n = 473) of patients: 82 % (n = 225) of them received intensive chemotherapy, 58 % (n = 248) – low-intensity chemotherapy. Relapses occurred in 41 % (n = 194) of 473 patients who achieved complete remission. In the first remission, allogeneic hematopoietic stem cell transplantation was performed in 11 % (n = 79) of patients. With a median follow-up of 30.1 months, the 3-year overall survival in total group was 27 % (95 % confidence interval 23–32), and the 3-year relapse-free survival was 44 % (95 % confidence interval 37–51).Conclusion. The main problem in the treatment of adult AML patients remains high induction mortality and limited opportunities for allogeneic hematopoietic stem cell transplantation in real clinical practice, which emphasizes the need to develop transplant centers in Moscow.

24 December 2021 in Blood
Verified
Journal Article
Open access
KKKsenia V. Kaluzhskaya
Ksenia V. Kaluzhskaya
YPYuri Yu. Polyakov
Yuri Yu. Polyakov
EBElena A. Baryakh
Elena A. Baryakh
EGEduard G. Gemdzhian
Eduard G. Gemdzhian
EMElena N. Misyurina
Elena N. Misyurina
DFDenis A. Fedorenko
Denis A. Fedorenko
Background: According to published data, the risk of coronavirus infection (COVID-19) in patients with malignancies is 5 times higher than in those without malignancies. Objective: To evaluate in-hospital overall survival in hematological patients with grade 4 neutropenia associated with coronavirus infection. Patients: This study was conducted from April 24, 2020 to June 17, 2021 in the Department of Hematology of Moscow City Clinical Hospital No. 52 (Russian Federation) and included 76 hematological patients with grade 4 neutropenia and coronavirus infection (aged 18-91 years): • 40 patients with acute leukemias (32 with AML, 8 with ALL): 22 men with a median age of 54 years (interquartile range (IQR) 43-60) and 18 women with a median age of 61 years (IQR 56-70) and • 36 patients with lymphoproliferative diseases (mostly with aggressive non-Hodgkin's lymphomas): 13 men with a median age of 57 years (IQR 40-68) and 23 women with a median age of 63 years (IQR 35-75). All patients were brought in by ambulance from other hospitals where they had received a course of combination chemotherapy interrupted due to coronavirus infection. Results: Most pts had moderate to severe lung disease (CT severity scores were 2, 3, and 4 in 29 (38.2%), 17 (22.5%), and 8 (10%) patients, respectively); 55% of patients had high C-reactive protein and procalcitonin (above 0.5 ng/mL); lactate dehydrogenase (mean 395.7 U/L) and D-dimer (mean 2533.8) levels were significantly elevated. Patients had a higher NEWS score (mean 8) and a high Charlson comorbidity index score (mean 5). Interleukin-6 and IL-1b blockers were used as pathogenetic therapy to control hypercytokinemia. Taking into account grade 4 neutropenia, the dose of interleukin blockers was reduced. In order to prevent thromboembolic complications, low molecular weight heparins were used at therapeutic doses (with anti-Xa activity monitoring). Oxygen was administered in patients with clinical signs of respiratory failure (oxygen insufflation via nasal cannulas or mask). Patients with progressive respiratory failure were transferred to intensive care unit. In order to improve humoral immune response (due to low SARS-CoV-2 IgG antibody titers), 43.4% of patients were administered replacement therapy with pathogen-reduced fresh-frozen COVID-19 convalescent plasma. This led to a pronounced IgG increase in 7 patients only. Antifungal treatment was used in 54% of cases. Empirical antibacterial treatment for community-acquired pneumonia was administered, including inhibitor-protected aminopenicillins and respiratory fluoroquinolones (as 1st line treatment), upfront antibacterial treatment for neutropenic fever (2nd line), and targeted antibacterial treatment (3rd line). • In the acute leukemia group, 25 (63%) patients died during hospital treatment and 15 (37%) subjects survived; the median overall survival was 15 days (95% CI 15-22) (Fig. 1). • In the lymphoproliferative disease group, the numbers of deaths and survivals were 22 (61%) and 14 (39%), respectively, and the median overall survival was 25 days (95% CI 11-32) (Fig. 2). The median follow-up was 24 days. Conclusions: Coronavirus infection associated with severe neutropenia (caused by tumor progression and/or combination chemotherapy) is a significant adverse factor for overall survival in patients with hematological malignancies.

14 January 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
OKO. L. Kochneva
O. L. Kochneva
EBE. A. Baryakh
E. A. Baryakh
EME. N. Misyurina
E. N. Misyurina
EZE. I. Zhelnova
E. I. Zhelnova
KYK. V. Yatskov
K. V. Yatskov
ЮПЮ. Ю. Поляков
Ю. Ю. Поляков
Background. At the end of 2019, a new coronavirus infection caused by the SARS-CoV-2 virus was registered. In March 2020, the first cases of COVID-19 were detected in Moscow. Patients with chronic lymphocytic leukemia, characterized by profound immune dysfunction, have risk factors for severe viral disease.Aim. To identify risk factors for hospital mortality and severe course of COVID-19, as well as to optimize therapeutic and preventive measures.Materials and methods. The analysis included 238 patients (142 (59 %) men and 96 (41 %) women) with chronic lymphocytic leukemia and COVID-19 with a median age of 66 (37-90) years, who were hospitalized at City Clinical Hospital No. 52 (Moscow) between April 2020 and April 2023. To compare hospital mortality and severity of COVID-19, patients were divided into 2 groups depending on the hospitalization period: 2020-2021 and 2022-2023, which correlates with the prevalence of some SARS-CoV-2 variants from December 2021 and changes in Moscow epidemiological situation.Results. Overall hospital mortality rate in 2020-2021 was 25 % (n = 45). Age over 73 years was a significant unfavorable factor in men. Cardiovascular diseases increase the risk of death by 2.3 times. Patients with a Charlson Comorbidity Index of 6 or more have a 2.2 times greater risk of death. A history of 1 or more lines of immunochemotherapy increased the risk of hospital mortality by 1.5 times. Relapse/progression of the disease were factors of unfavorable prognosis for patient survival. Binet stage C also showed a significant unfavorable prognosis. When studying all cases of death (n = 51), complications such as myelotoxic agranulocytosis, secondary bacterial complications and severe interstitial pulmonary damage 75 % were identified.Conclusion. Coronavirus infection caused by SARS-CoV-2 represents an infectious threat among patients with chronic lymphocytic leukemia and may affect the regimen and tactics of antitumor therapy. The use of a full range of preventive measures, vaccination and pre-exposure prophylaxis in this cohort of patients is of great importance.